作者
Mauro Biffi,Eduardo Celentano,Massimo Giammaria,Antonio Curnis,Giovanni Rovaris,Matteo Ziacchi,Gennaro Miracapillo,Davide Saporito,Matteo Baroni,Fabio Quartieri,Massimiliano Marini,Patrizia Pepi,Gaetano Senatore,Fabrizio Caravati,Valéria Calvi,Luca Tomasi,Gerardo Nigro,Luca Bontempi,Francesca M. Notarangelo,Vincenzo Ezio Santobuono,Giulio Boggian,Giuseppe Arena,Francesco Solimene,Marzia Giaccardi,Giampiero Maglia,Alessandro Paoletti Perini,Mario Volpicelli,Daniele Giacopelli,Alessio Gargaro,Saverio Iacopino
摘要
Abstract
Background
Atrial high-rate episodes (AHRE) are frequent in patients with cardiac implantable electronic devices. A decrease in device-detected P-wave amplitude may be an indicator of periods of increased risk of AHRE. Objective
To assess the association between P-wave amplitude and AHRE incidence. Methods
Remote monitoring data from 2,579 patients with no history of atrial fibrillation (23% pacemakers, 77% implantable cardioverter-defibrillators [ICDs] of which 40% providing cardiac resynchronization therapy [CRT]) were used to calculate the mean P-wave amplitude during 1 month after implantation. The association with AHRE incidence according to four strata of daily burden duration (≥15 minutes, ≥6 hours, ≥24 hours, ≥7 days) was investigated by adjusting the hazard ratio with the CHA2DS2-VASc score. Results
The adjusted hazard ratio (HR) for 1-mV lower mean P-wave amplitude during the first month increased from 1.10 (95% confidence interval [CI], 1.05-1.15; p<0.001) to 1.18 (CI, 1.09-1.28; p<0.001) with AHRE duration strata from ≥15 minutes to ≥7 days independently of the CHA2DS2-VASc score. Among 871 patients with AHREs, those with 1-month P-wave amplitude <2.45 mV had an adjusted HR of 1.51 (CI, 1.19-1.91; p=0.001) for progression from ≥15 minutes to ≥7 days AHREs compared to those with 1-month P-wave amplitude ≥2.45 mV. Device-detected P-wave amplitudes decreased linearly during the one year before the first AHRE by 7.3% (CI, 5.1%-9.5%, p<0.001 versus patients without AHRE). Conclusion
Device-detected P-wave amplitudes lower than 2.45 mV were associated with an increased risk of AHRE onset and progression to persistent forms of AHRE independently of the patient's risk profile.